M
Marco Lucchi
Researcher at University of Pisa
Publications - 225
Citations - 11205
Marco Lucchi is an academic researcher from University of Pisa. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 47, co-authored 199 publications receiving 9227 citations.
Papers
More filters
Journal ArticleDOI
Thymectomy in ocular myasthenia gravis.
Journal ArticleDOI
P2.01-018 Differential microRNA Expression Profile between Young and Old Lung Adenocarcinoma Patients: Topic: Analysis of RNA
Mirella Giordano,Laura Boldrini,Adele Servadio,Marco Lucchi,Franca Melfi,Alfredo Mussi,Gabriella Fontanini +6 more
Journal ArticleDOI
Pathological and clinical features of multiple cancers and lung adenocarcinoma: a multicentre study
Pietro Bertoglio,G. Ventura,Vittorio Aprile,Maria Cattoni,Dania Nachira,Filippo Lococo,Maria Rodriguez Perez,Francesco Guerrera,Fabrizio Minervini,Letizia Gnetti,A Lenzini,Francesca Franzi,Giulia Querzoli,Guido Rindi,Salvatore Bellafiore,Federico Femia,Giuseppe Bogina,Diana Bacchin,Peter Kestenholz,Enrico Ruffini,Massimiliano Pau,Stefano Margaritora,Andrea Imperatori,Marco Lucchi,Luca Ampollini,Alberto Terzi +25 more
TL;DR: In patients with PC, smaller tumours are found more frequently treated with minimally invasive techniques and sublobar resection, probably due to a more careful follow-up, and the impact on survival is not uniform and predictable; however, breast and colon cancers and melanoma showed a lower incidence of solid or micropapillary patterns whereas patients with lymphomas had a higher incidence of a micropAPillary pattern.
Percutaneous radiofrequency ablation (pRTA) of pulmonary tumors
Marcello Carlo Ambrogi,Riccardo Lencioni,Olivia Fanucchi,G. Fontanini,Marco Lucchi,Alessandro Ribechini,Alfredo Mussi,Ca Angeletti +7 more
Journal ArticleDOI
Distinct Angiogenic microRNA-mRNA Expression Profiles Among Subtypes of Lung Adenocarcinoma.
TL;DR: A distinct angiogenic miRNA-mRNA expression profile among the subtypes of ADC, with a putative clinical application to stratify patients for anti-angiogenetic drugs, is suggested.